Serum levels of TRAIL were significantly decreased in AMI patients at baseline (compared to healthy controls) and low TRAIL levels at patient discharge were associated with increased incidence of cardiac death and heart failure at the 12-month follow-up, even after adjustment for demographic and clinical risk parameters. This evidence concerns the gene TNFSF10 and heart failure.